NeoGenomics (NASDAQ: NEO) reported Q2 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $146.92 million versus the consensus estimate of $137.42 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.